Regulation of human research with LSD in the United States (1949-1987)

  title={Regulation of human research with LSD in the United States (1949-1987)},
  author={Katherine R Bonson},
  • K. Bonson
  • Published 1 February 2018
  • Psychology, Medicine
  • Psychopharmacology
Human research with hallucinogens such as lysergic acid diethylamide (LSD) has been ongoing in the USA since 1949. During the 1960s, LSD was investigated for a variety of psychiatric indications, including the following: as an aid in treatment of schizophrenia; as a means of creating a “model psychosis”; as a direct antidepressant; and as an adjunct to psychotherapy. Studies with all drugs, including LSD, have always been conducted under federal regulatory controls, including the 1938 Food Drug… 

Why was early therapeutic research on psychedelic drugs abandoned?

  • W. Hall
  • Medicine, Psychology
    Psychological Medicine
  • 2021
The demise of psychedelic drug research was not solely due to the ‘War on Drugs’, but was hastened by tighter regulation of pharmaceutical research, the failure of controlled clinical trials to live up to the claims of psychedelic advocates, and the pharmaceutical industry's lack of interest in funding clinical trials.

Psychedelics: Where we are now, why we got here, what we must do

Psychedelic Medicines in Major Depression: Progress and Future Challenges.

The main neurobiological mechanisms of psychedelic drugs will be described, noting that while some of these mechanisms could be potentially associated with their therapeutic properties, they are commonly used as adjuvants in psychotherapeutic processes.

Psychedelics as an emerging novel intervention in the treatment of substance use disorder: a review.

The aim of this review is to examine the current standing of evidence regarding psychedelic psychopharmacology and to provide an overview of the use and effectiveness of these drugs in the treatment of SUD, alcohol use disorder, and for smoking cessation.

From psychiatry to neurology: Psychedelics as prospective therapeutics for neurodegenerative disorders

Recent findings and information on how psychedelics may act therapeutically on cells within the central nervous system (CNS) during brain injuries and neurodegenerative diseases are discussed.

Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions

An overview of past and present models of psychedelic therapy is provided, and important considerations for future interventions incorporating the use of psychedelics in research and clinical practice are discussed.



Efficacy and Enlightenment: LSD Psychotherapy and the Drug Amendments of 1962

  • M. Oram
  • Psychology
    Journal of the history of medicine and allied sciences
  • 2014
A new perspective is provided on the death of LSD psychotherapy and the implications of the Drug Amendments of 1962 are explored, which explore how the new emphasis on controlled clinical trials frustrated the progress of LSD Psychotherapy research by focusing researchers’ attention on trial design to the detriment of their therapeutic method.

LSD before Leary: Sidney Cohen's Critique of 1950s Psychedelic Drug Research

In 1962 Sidney Cohen presented the medical community with its first warning about the dangers of the drug LSD, and the subsequent government crackdown and regulation of LSD preceded the 1960s drug movement and was prompted by medical, not social, concerns.

The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future

In this circumspective piece, RLC-H and GMG share their opinions on the promises and pitfalls of renewed psychedelic research, with a focus on the development of psilocybin as a treatment for depression.

Psychiatric Research with Hallucinogens: What have we learned?

After a twenty-five year period of virtual prohibition, formal psychiatric research with hallucinogenic drugs has resumed. This article reviews the process by which hallucinogens came to be viewed as

Treatment of alcoholism using psychedelic drugs: a review of the program of research.

  • M. Mangini
  • Psychology
    Journal of psychoactive drugs
  • 1998
The history of one branch of psychedelic research, the therapeutic use of LSD in the treatment of alcoholism, and of the events that led to the relabeling of the "hallucinogens" as drugs of abuse are explored.

A Brief History of Placebos and Clinical Trials in Psychiatry

  • E. Shorter
  • Psychology, Medicine
    Canadian journal of psychiatry. Revue canadienne de psychiatrie
  • 2011
The history of placebos in psychiatry can be understood only in the context of randomized controlled trials (RCTs), and the dogma of the placebo-controlled trial as the only acceptable data for drug licensing is also being increasingly discredited.


Bizarre visual phenomena, ranging from a heightening of the apparent brightness or beauty of colored objects in the environment, through distortions in the perceived nature or meaning of real objects (illusions) to true visual hallucinations of colors, shapes, or even of complex scenes or events are reported.

Lysergic Acid Diethylamide

I believe and hope that this petulant and ill-considered decision may be revoked, failing which action there can be little doubt that much more damage will be done to the public image of Sandoz than could ever have resulted from misuse of a drug which in any case is now in the U.S.A. freely available from illicit sources.

Experimental schizophrenia-like symptoms.

1. The effects of minute amounts of dlysergic acid diethylamide tartrate (L. S. D.) on normal subjects, with an age range of 19-48 years, and some psychotic patients of the schizophrenic, depressive,